Oriola Oyj (ORIOLA) Fair Value & Analysis
Healthcare · FI · Market cap €170M
Fair value as of: Jul 12, 2026
From 15 valuation models · updated 29 days ago
Fair value updated Jul 12, 2026, revised from €1.64 to €0.7200 (−56.1%) since Jun 24, 2026. Share price −2.5% over the past month.
A solid business, but screening 20% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€0.7200). The favourable scenario is already priced in.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (€0.7100 to €0.7200), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range €0.7607 – €1.84 · fair‑value band €0.7100 – €0.7200 · the €0.9020 price screens above the €0.7200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Oriola Oyj (ORIOLA) currently trades at €0.9020, while our model-based Fair Value estimate is €0.7200, implying the stock looks roughly 20.2% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Oriola Oyj generated revenue of €1.9B at a net margin of -1.3%. Revenue declined 2.2% year over year. It earns a return on equity of -21.1%. The balance sheet holds a net cash position of €73.9M. Fundamentals as of Jul 12, 2026
Our scenario range runs from €0.7100 (bear case) to €0.7200 (bull case); at €0.9020, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -20%, ORIOLA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (€2.73) versus Asset-Based (€0.3700). Highest evidence: Growth DCF (80).
Notify me when ORIOLA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products.
Full company description
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Oriola Oyj reported revenue of €1.9B in FY2025 versus €1.5B in FY2021, a compound +7.0%/yr. Reported net income was −€27.2M in FY2025.
ORIOLA screens 20% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Oriola Oyj with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Oriola Oyj (ORIOLA) overvalued or undervalued?
What is the fair value of ORIOLA?
What is the quality score of ORIOLA?
What is the revenue of Oriola Oyj (ORIOLA)?
What is the net profit margin of ORIOLA?
Does Oriola Oyj pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Oriola Oyj and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.